Related Experiment Video
Updated: Jun 18, 2026
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Immunizing against breast cancer: a new swing for an old sword
Giuseppe Curigliano1, Marzia Locatelli, Luca Fumagalli
1European Institute of Oncology, Department of Medicine, Division of Medical Oncology, Via Ripamonti 435, Milan, Italy. giuseppe.curigliano@ieo.it
Abstract:
Therapeutic potential of vaccination has been explored in many clinical trials involving patients with breast cancer. A large variety of cancer immunogens have been tested. The majority of clinical vaccination studies have been carried out in patients with metastatic breast cancer, characterized by extremely aggressive malignant tumors, resistant to all standard cytotoxic treatments and with longest-lasting disease. With active specific immunotherapy, tumor-associated antigens coupled to appropriate adjuvant can elicit a powerful antitumor responses. The potential advantages of therapeutic cancer vaccines are that they can augment an established immunogenic response to the tumor (which is generally weak in breast cancer), they target specific tumor antigens (although there are few), they are potentially non-toxic, they can be combined with conventional therapies and/or other immunotherapies, and they elicit immunologic memory to prevent recurrence of the tumor. It is unclear whether therapeutic vaccines for cancer prolong survival. Data of clinical activity have been observed by using vaccines targeting HER-2/neu protein, human telomerase reverse transcriptase, carcinoembryonic antigen (CEA), and carbohydrate antigen given after stem cell rescue. A better understanding of the relation between innate and adaptive immune responses, and of the immune escape mechanisms employed by tumor cells, the discovery of mechanisms underlying immunological tolerance, and acknowledgment of the importance of both cell-mediated and humoral adaptive immunity for the control of tumour growth are necessary for leading to a more comprehensive immunotherapeutic approach in breast cancer.
Insights
Therapeutic cancer vaccines show potential for breast cancer treatment by eliciting antitumor responses and preventing recurrence. Further research is needed to understand immune responses and improve therapeutic strategies.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Therapeutic vaccination is being explored in clinical trials for breast cancer, particularly for metastatic disease resistant to conventional treatments.
- Active specific immunotherapy utilizes tumor-associated antigens and adjuvants to stimulate antitumor immune responses.
- Breast cancer often exhibits a weak endogenous immune response to tumors, necessitating immunotherapeutic augmentation.
Purpose of the Study:
- To review the therapeutic potential and clinical activity of cancer vaccines in breast cancer treatment.
- To explore the advantages and limitations of therapeutic cancer vaccines, including their role in preventing tumor recurrence.
- To identify key areas for future research to advance immunotherapeutic approaches for breast cancer.
Main Methods:
- Review of clinical vaccination studies in breast cancer patients.
- Analysis of vaccines targeting specific tumor antigens such as HER-2/neu, human telomerase reverse transcriptase, carcinoembryonic antigen (CEA), and carbohydrate antigens.
- Consideration of vaccine administration in conjunction with stem cell rescue and conventional therapies.
Main Results:
- Clinical activity has been observed with vaccines targeting specific antigens like HER-2/neu and CEA, particularly when administered post-stem cell rescue.
- Potential benefits include augmenting weak anti-tumor responses, targeting specific antigens, low toxicity, and inducing immunologic memory.
- The impact of therapeutic cancer vaccines on overall survival remains unclear.
Conclusions:
- Therapeutic cancer vaccines offer a promising avenue for breast cancer treatment, with potential to enhance immune responses and prevent recurrence.
- Further understanding of innate and adaptive immunity, tumor immune escape mechanisms, immunological tolerance, and the interplay of immune components is crucial.
- A comprehensive immunotherapeutic strategy requires integrating this knowledge to improve treatment efficacy in breast cancer.
More Related Videos
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:59Cancer Prevention
Some...
02:59Cancer Prevention
Some...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...